Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1

被引：0

作者：

Marmarelis, M. E. ^{[1
]}

Mathew, D. ^{[1
]}

Bauml, J. M. ^{[2
]}

Hwang, W. -T. ^{[1
]}

Zhang, J. ^{[1
]}

Singh, A. ^{[1
]}

D'Avella, C. ^{[1
]}

Davis, C. ^{[1
]}

Ye, D. ^{[1
]}

Sun, L. ^{[1
]}

Ciunci, C. ^{[1
]}

Zhang, N. ^{[1
]}

Aggarwal, C. ^{[1
]}

Cohen, R. B. ^{[1
]}

Minn, A. J. ^{[1
]}

Wherry, E. J. ^{[1
]}

Langer, C. J. ^{[1
]}

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] Janssen, Philadelphia, PA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期

关键词：

Immunotherapy; JAK; pembrolizumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.15-07

引用

页码：S122 / S123

页数：2

共 50 条

[1] Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up
Marmarelis, M. E.
Cantor, D. J.
Mathew, D.
McWilliams, T.
Bauml, J.
Hwang, W-T
Singh, A.
D'Avella, C.
Davis, C.
Ye, D.
Sun, L.
Ciunci, C.
Aggarwal, C.
Cohen, R. B.
Minn, A.
Wherry, J.
Langer, C. J.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S20 - S20
[2] The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors
Schakenraad, Alexandra
Hashemi, Sayed
Twisk, Jos
Houda, Ilias
Ulas, Ezgi
Daniels, Johannes M. A.
Veltman, Joris
Bahce, I.
LUNG CANCER, 2021, 162 : 36 - 41
[3] Real World Data of First-Line Treatment With Pembrolizumab for Highly PD-L1-Expressing NSCLC
Kobayashi, M.
Mizugaki, H.
Ikezawa, Y.
Morita, R.
Tateishi, K.
Yokoo, K.
Sumi, T.
Kikuchi, H.
Nagano, Y.
Nakamura, A.
Aso, M.
Kimura, N.
Yoshiike, F.
Furuta, M.
Tanaka, H.
Sekikawa, M.
Hachiya, T.
Fujita, Y.
Oizumi, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1017 - S1017
[4] Real-world data of first-line treatment with pembrolizumab for highly PD-L1 expressing NSCLC (HOT/NJLCG2001)
Nakamura, A.
Mizugaki, H.
Ikezawa, Y.
Morita, R.
Tateishi, K.
Yokoo, K.
Sumi, T.
Kikuchi, H.
Kitamura, Y.
Morita, M.
Aso, M.
Tsukita, Y.
Yoshiike, F.
Furuta, M.
Tanaka, H.
Sekikawa, M.
Hachiya, T.
Nakamura, K.
Yokouchi, H.
ANNALS OF ONCOLOGY, 2021, 32 : S1008 - S1008
[5] Phase III Trial of Pembrolizumab-Chemotherapy Versus Pembrolizumab in First-Line of Advanced NSCLC with PD-L1 ≥50%: PERSEE
Descourt, R.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1011 - S1011
[6] An Indirect Comparison of Pembrolizumab Monotherapy Versus Ipilimumab plus Nivolumab for First-Line Metastatic NSCLC with PD-L1 TPS≥1%
Halmos, B.
Burke, T.
Kalyvas, C.
Insinga, R.
Vandormael, K.
Frederickson, A.
Piperdi, B.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S23 - S24
[7] Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC
Wan, Ning
Zhang, Tian-tian
Hua, Si-hua
Lu, Zi-luo
Ji, Bo
Li, Li-xia
Lu, Li-qing
Huang, Wen-jie
Jiang, Jie
Li, Jian
CANCER MEDICINE, 2020, 9 (05): : 1683 - 1693
[8] Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab
Stares, Mark
Doyle, Emma
Chapple, Sally
Raynes, George
MacDonald, James
Barrie, Colin
Laird, Barry
MacKean, Melanie
Philips, Iain
LUNG CANCER, 2024, 189
[9] First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort
Amrane, K.
Geier, M.
Corre, R.
Leveiller, G.
Florence, G.
Lamy, R.
Bizec, J. L.
Goarant, E.
Robinet, G.
Ulrike, S.
Quere, G.
Bernier, C.
Descourt, R.
ANNALS OF ONCOLOGY, 2019, 30
[10] PD-L1 expression in primary tumour vs metastatic samples in the phase III MYSTIC study in first-line metastatic (m) NSCLC
Reinmuth, N.
Boothman, A-M.
Cho, B. C.
Lee, K. H.
Luft, A.
Ahn, M-J.
Scott, M.
Whiteley, J.
Walker, J.
Karwe, V.
Mukhopadhyay, P.
Thiyagarajah, P.
Scheuring, U.
Rizvi, N.
ANNALS OF ONCOLOGY, 2019, 30 : 611 - 611

← 1 2 3 4 5 →